GLP Pre clinical Rodent Studies of ZAG as an Anti-obesity, Anti-Diabetic Therapeu

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$181,994.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK085977-01A1
Award Id:
96049
Agency Tracking Number:
DK085977
Solicitation Year:
n/a
Solicitation Topic Code:
NIDDK
Solicitation Number:
n/a
Small Business Information
HALSA PHARMACEUTICALS, INC., 8822 WESTVIEW DR, HOUSTON, TX, 77055
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
786722566
Principal Investigator:
PHILIP SPEROS
(832) 722-0513
PSPEROS@HALSAPHARMA.COM
Business Contact:
PHILIP SPEROS
() -
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Halsa has acquired the exclusive intellectual property rights to ZAG, a material naturally found in humans, which induces immediate and substantial depletion of body fat as well as control of diabetic symptoms. A growin g set of evidence shows that this therapeutic works in depleting body fat. Over 65% of Americans are overweight or obese, the costs of these conditions is estimated as 150 billion (half in actual health care costs), and the market for an effective prescri ption weight-loss therapeutic is estimated at 18 billion annually. Halsa has assembled a world-class team with exact domain expertise in pharmaceutical drug development. This project will lay the foundation for ZAG to enter full preclinical trials in prep aration of an IND filing with the FDA, and subsequent clinical trials. This SBIR Phase I project will result in exploratory GLP toxicological studies in rats, a critical step in understanding possible liabilities for this promising therapeutic agent. The t hree specific aims of this project are: manufacture of the biologic agent, determination of its potency and toxicology studies including histopathology. PUBLIC HEALTH RELEVANCE: Obesity and overweight are epidemic, dangerous, expensive and largely u ntreated. Halsa is developing a biological drug, ZAG, a material naturally found in humans, which induces immediate and substantial depletion of body fat and also controls symptoms of diabetes. This therapeutic candidate has the potential to treat the near ly 200 million Americans afflicted with these deleterious metabolic diseases.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government